HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy.

Abstract
Cannabinoids are neuroprotective in models of neurodegenerative dementias. Their effects are mostly mediated through CB1 and CB2 receptor-dependent modulation of excitotoxicity, inflammation, oxidative stress, and other processes. We tested the effects of Sativex®, a mixture of Δ9-tetrahydrocannabinol and cannabidiol, acting on both CB1 and CB2 receptors, in parkin-null, human tau overexpressing (PK-/-/TauVLW) mice, a model of complex frontotemporal dementia, parkinsonism, and lower motor neuron disease. The animals received Sativex®, 4.63 mg/kg, ip, daily, for one month, at six months of age, at the onset of the clinical symptoms. We evaluated the effects of Sativex® on behavior, dopamine neurotransmission, glial activation, redox state, mitochondrial activity, and deposition of abnormal proteins. PK-/-/TauVLW mice developed the neurological deficits, but those treated with Sativex® showed less abnormal behaviors related to stress, less auto and hetero-aggression, and less stereotypy. Sativex® significantly reduced the intraneuronal, MAO-related free radicals produced during dopamine metabolism in the limbic system. Sativex® also decreased gliosis in cortex and hippocampus, increased the ratio reduced/oxidized glutathione in the limbic system, reduced the levels of iNOS, and increased those of complex IV in the cerebral cortex. With regard to tau and amyloid pathology, Sativex® reduced the deposition of both in the hippocampus and cerebral cortex of PK-/-/TauVLW mice and increased autophagy. Sativex®, even after a short administration in animals with present behavioral and pathological abnormalities, improves the phenotype, the oxidative stress, and the deposition of proteins in PK-/-/TauVLW mice, a model of complex neurodegenerative disorders.
AuthorsMaria J Casarejos, Juan Perucho, Ana Gomez, Maria P Muñoz, Marian Fernandez-Estevez, Onintza Sagredo, Javier Fernandez Ruiz, Manuel Guzman, Justo Garcia de Yebenes, Maria A Mena
JournalJournal of Alzheimer's disease : JAD (J Alzheimers Dis) Vol. 35 Issue 3 Pg. 525-39 ( 2013) ISSN: 1875-8908 [Electronic] Netherlands
PMID23478312 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biogenic Monoamines
  • Drug Combinations
  • Neuroprotective Agents
  • Plant Extracts
  • Cannabidiol
  • Dronabinol
  • Glutathione
  • nabiximols
  • Dopamine
Topics
  • Amyloidosis (pathology, physiopathology)
  • Animals
  • Behavior, Animal (drug effects, physiology)
  • Biogenic Monoamines (metabolism)
  • Cannabidiol
  • Disease Models, Animal
  • Dopamine (physiology)
  • Dronabinol
  • Drug Combinations
  • Frontotemporal Dementia (pathology, physiopathology)
  • Glutathione (metabolism)
  • Humans
  • Male
  • Mice
  • Mice, Neurologic Mutants
  • Mice, Transgenic
  • Neuroprotective Agents (pharmacology)
  • Phytotherapy
  • Plant Extracts (pharmacology)
  • Synaptic Transmission (drug effects, physiology)
  • Tauopathies (pathology, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: